Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats (1)

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.

Novo can now meet the demand for Ozempic and Wegovy nationwide, the Food and Drug Administration said Friday. The ruling shows Novo’s confidence that the supply of Ozempic will be stable for now. It’s also a sign that the billions of dollars the drugmaker has poured into factory construction are paying off. That puts the Danish drugmaker into a better position to compete with US rival Eli ...